D.E. Shaw & Co
RAPT

D.E. Shaw & Co’s RAPT Therapeutics RAPT Stock Holding History

D.E. Shaw & Co’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,490
Closed -$102K – 4657
2025
Q1 		$102K Sell
10,490
-85,762
-89% -$843K ﹤0.01% 4015
2024
Q4 		$1.22M Sell
96,252
-34,771
-27% -$442K ﹤0.01% 3094
2024
Q3 		$2.11M Buy
131,023
+17,596
+16% +$356K ﹤0.01% 2672
2024
Q2 		$2.77M Buy
113,427
+79,659
+236% +$3.68M ﹤0.01% 2333
2024
Q1 		$2.43M Buy
+33,768
New +$4.69M ﹤0.01% 2479
2023
Q3 		– Sell
-2,142
Closed -$320K – 4441
2023
Q2 		$320K Sell
2,142
-9,866
-82% -$1.54M ﹤0.01% 3581
2023
Q1 		$1.76M Sell
12,008
-3,830
-24% -$775K ﹤0.01% 2780
2022
Q4 		$2.51M Buy
15,838
+3,403
+27% +$545K ﹤0.01% 2742
2022
Q3 		$2.39M Buy
+12,435
New +$2.35M ﹤0.01% 2841
2022
Q1 		– Sell
-8,581
Closed -$2.52M – 5861
2021
Q4 		$2.52M Sell
8,581
-7,390
-46% -$1.98M ﹤0.01% 3136
2021
Q3 		$3.97M Buy
15,971
+9,986
+167% +$2.64M ﹤0.01% 2342
2021
Q2 		$1.52M Buy
+5,985
New +$1.12M ﹤0.01% 3197

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

D.E. Shaw & Co's RAPT Position: Q2 2025 in Review

D.E. Shaw & Co sold out of RAPT Therapeutics (RAPT) in Q2 2025, closing a stake of 10,490 shares — an estimated $102K sold.

D.E. Shaw & Co first reported a position in RAPT in Q2 2021 and held it in 12 quarters. The position peaked at $3.97M in Q3 2021. 50 funds tracked by Wall St. Rank hold RAPT as of Q2 2025.

  • D.E. Shaw & Co reported no remaining RAPT Therapeutics position as of Q2 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 10,490 RAPT Therapeutics shares in Q2 2025, an estimated $102K.
  • D.E. Shaw & Co first reported a position in RAPT Therapeutics in Q2 2021 and held it in 12 quarters.
  • D.E. Shaw & Co's RAPT Therapeutics position peaked at $3.97M in Q3 2021.
  • 50 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.